Lupin has launched Flucytosine capsules, used to treat serious infections, in the American market. The company has launched its generic product in the strengths of 250 mg and 500 mg after having received approval from the US Food and Drug Administration (USFDA), Lupin said in a regulatory filing.
The Mumbai-based company’s product is the generic version of Valeant Pharmaceuticals International Inc’s Ancobon tablets.The drug is indicated for the treatment of serious infections. As per the latest IMS sales data, Flucytosine capsules have annual sales of around $48 million in the US.
Lupin shares ended up by 2.38 per cent Rs 898.40 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.